Dizal Pharmaceutical Co Ltdis A Global Biopharmaceutical Company Based In Chinafocused On Developing Innovative Therapeutics For Cancer And Immunological Diseaseswith A Team Of 581 Employeesdizal Emphasizes Translational Science To Connect Preclinical Research With Clinical Developmentaiming To Meet Unmet Medical Needs In Oncology And Immunology The Company Offers Targeted Therapies Such As Sunvozertinibdesigned For Advanced Non Small Cell Lung Cancernsclcwith Specific Mutationsand Golidocitinibaimed At Treating Hematologic Malignanciesdizal Has A Robust Pipeline That Includes Several Candidates Targeting Various Cancers And Immunological Disordersthe Company Is Actively Engaged In Regulatory Processesincluding A New Drug Application Submitted To The U Sfda For Sunvozertiniband Plans To Present Clinical Data At Asco 2025
